Regulated information
Waregem (Belgium)/Rotterdam (The Netherlands)1, 25 April 2016
Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification on 22 April 2016 that the shareholding of The Goldman Sachs Group, Inc. had fallen below the disclosure threshold of 3% on 18 April 2016 as the result of the disposal of voting securities or voting rights.
The notification of The Goldman Sachs Group, Inc. can be viewed on investors.fagron.com via this link.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
For more information:
Constantijn van Rietschoten
Chief Marketing Officer
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com
Fagron profile
Fagron is a scientific pharmaceutical R&D business focused on optimising and innovating personalised pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
1 This press release was sent out by Fagron NV and Fagron BV.
Please open the link below for the press release: